

In the Claims:

Claims 1-24 (Cancelled)

1 25. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) ~~the an~~ amino acid sequence SEQ ID NO:2 ~~matching one of SEQ ID NOs:2 or 4;~~
- (b) an immunogenic ~~polypeptide comprising a~~ fragment sequence of at least contiguous 15 amino acids of SEQ ID NO:2 ~~that matches an aligned contiguous segment of one of SEQ ID NOs:2 or 4;~~

wherein the immunogenic fragment ~~isolated polypeptide~~, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the ~~to a~~ polypeptide SEQ ID NO:2 ~~having the sequence of one of SEQ ID NOs:2 or 4.~~

26. (Cancelled)

2 27. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

3 29. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

4 31. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the isolated polypeptide, when administered to a subject in a suitable composition which

can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

5 ~~32.~~ (Currently Amended): The isolated, recombinant polypeptide of Claim ~~25~~⁰ wherein the isolated, recombinant polypeptide of (a) consists of SEQ ID NO:2 ~~one of SEQ ID NOs: 2 or 4.~~

Claims 33-34 (Cancelled)

6 ~~35.~~ (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim ~~25~~. 1

Claims 36-39 (Cancelled)

7 ~~40.~~ (Currently Amended): An immunogenic composition A vaccine comprising the isolated, recombinant polypeptide of Claim ~~25~~ and a pharmaceutically acceptable carrier.

8 ~~41.~~ (Currently Amended): The immunogenic composition of Claim ~~40~~⁷, wherein the immunogenic composition vaccine comprises at least one other *Moraxella catarrhalis* antigen in addition to the antigen provided by the isolated recombinant polypeptide.

42. (Cancelled)

9 ~~43.~~ (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim ~~25~~. 1

Claims 44-46 (Cancelled)

10 ~~47.~~ (New): A fusion protein comprising the isolated, recombinant polypeptide of Claim ~~27~~².

11 ~~48.~~ (New): A fusion protein comprising the isolated, recombinant polypeptide of Claim ~~29~~³.

12 ~~49.~~ (New): An immunogenic composition comprising the isolated, recombinant polypeptide
of claim ~~27.~~ 2

13 ~~50.~~ (New): An immunogenic composition comprising the isolated, recombinant polypeptide
of claim ~~29.~~ 3

14 ~~51.~~ (New): An isolated polypeptide consisting of SEQ ID NO:2.